# Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

> **NCT01641809** · PHASE2 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 244 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** GSK1265744 10 mg
- **DRUG:** GSK1265744 30 mg
- **DRUG:** GSK1265744 60 mg
- **DRUG:** Efavirenz 600 mg
- **DRUG:** Rilpivirine 25 mg
- **DRUG:** Placebo
- **DRUG:** Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)

## Key facts

- **NCT ID:** NCT01641809
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-06
- **Primary completion:** 2013-10-10
- **Final completion:** 2019-01-15
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2020-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641809, "Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01641809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*